Department of Biochemistry and Molecular Biology, Institute of Glycobiology, Dalian Medical University, Dalian, China.
Department of Urology, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Front Immunol. 2021 Mar 9;12:639636. doi: 10.3389/fimmu.2021.639636. eCollection 2021.
Renal cell carcinoma is a highly heterogeneous cancer group, and the complex microenvironment of the tumor provides appropriate immune evasion opportunities. The molecular mechanism of immune escape in renal cell carcinoma is currently a hot issue, focusing primarily on the major complex of histocompatibility, immunosuppressive cells, their secreted immunosuppressive cytokines, and apoptosis molecule signal transduction. Immunotherapy is the best treatment option for patients with metastatic or advanced renal cell carcinoma and combination immunotherapy based on a variety of principles has shown promising prospects. Comprehensive and in-depth knowledge of the molecular mechanism of immune escape in renal cell carcinoma is of vital importance for the clinical implementation of effective therapies. The goal of this review is to address research into the mechanisms of immune escape in renal cell carcinoma and the use of the latest immunotherapy. In addition, we are all looking forward to the latest frontiers of experimental combination immunotherapy.
肾细胞癌是一组高度异质性的癌症,肿瘤的复杂微环境为免疫逃避提供了适当的机会。肾细胞癌免疫逃避的分子机制是目前的一个热点问题,主要集中在主要组织相容性复合体、免疫抑制细胞、其分泌的免疫抑制细胞因子和凋亡分子信号转导上。免疫疗法是转移性或晚期肾细胞癌患者的最佳治疗选择,基于多种原理的联合免疫疗法显示出了有前景的前景。全面深入地了解肾细胞癌免疫逃逸的分子机制对于临床实施有效的治疗方法至关重要。本综述的目的是探讨肾细胞癌免疫逃逸的机制以及最新免疫疗法的应用。此外,我们都期待着实验性联合免疫治疗的最新前沿。